Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor ...

Applying machine-learned algorithms and automated imaging on the Hi-Q organoids identified selumetinib and fulvestrant as potent inhibitors of GSC invasion. In a mouse glioma xenograft model ...

As our knowledge about aromatase inhibitors and their side effects has expanded, questions remain unanswered with regards to their influence on cognition. Future study designs evaluating cognitive ...